ArticleAnnals of medicine and surgery (2012)2026
Synergistic mechanism of Shengyang Shiyiwei Pill in enhancing bevacizumab efficacy for hepatocellular carcinoma-associated ascites.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC)-associated ascites remain a therapeutic challenge, with bevacizumab showing limited efficacy due to resistance. Shengyang Shiyiwei Pill (SYP), a traditional Chinese medicine, may offer a multi-targeted approach, but its synergistic mechanisms with bevacizumab require investigation. Methods: In an H22-induced ascites model, we assessed SYP-bevacizumab combination therapy by measuring survival, ascites volume, and molecular markers (VEGFA, CD31, Caspase-3). HepG2 cells were treated with SYP-containing serum to evaluate cell cycle arrest and ferroptosis (GPX4, iron levels). Network pharmacology identified SYP's bioactive compounds and potential targets, followed by bioinformatics validation (TNMplot, HCCDB) and molecular docking analysis. Results: The SYP-bevacizumab combination significantly reduced ascites volume and prolonged survival. Mechanistically, it downregulated VEGFA/CD31 while upregulating Caspase-3. SYP induced G0/G1-S phase-arrest and ferroptosis in HepG2 cells. Network pharmacology revealed quercetin and kaempferol as key active components targeting G6PD, with molecular docking confirming strong binding interactions. Bioinformatics analysis demonstrated that high G6PD expression correlated with poor HCC prognosis and immune cell infiltration. SYP restored sorafenib sensitivity in resistant cells through G6PD inhibition. Conclusion: SYP enhances bevacizumab efficacy by targeting angiogenesis, ferroptosis, and G6PD-mediated resistance, providing a rationale for integrating traditional and modern therapies in HCC management. These findings highlight the value of network pharmacology in elucidating TCM mechanisms and support further clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.